Latest News & Features
In-house counsel
With patent validity increasingly being fought over in both the UPC and EPO, Genevant Sciences’ Stephan Kutik talks to LSIPR about keeping parallel proceedings aligned and why teamwork matters. 1 October 2026
Regulation & Industry
LSPN Europe made its Basel debut, and two days of conversations showed just how much is changing for life sciences professionals—both in how they work and what they are being asked to do. Marisa Woutersen tallies up the talking points. 1 October 2026
Pharma
The decision leaves a $177 million verdict against Lilly intact, but a dissenting judge has warned the ruling could “undermine medical innovation” by allowing overly broad patent claims to survive and provide a way around the Supreme Court’s Amgen decision. 1 October 2026
Regulation & Industry
The Third Circuit has upheld Thomson Reuters’ victory over Ross Intelligence in the first US appellate ruling on whether AI training can qualify as fair use. With the court’s reasoning still sealed, the case could have significant implications for AI developers using copyrighted content to build competing products. 30 September 2026
Biotech
The gene-editing company has accused a former employee of secretly co-founding a Chinese biotech while still at the company, in a trade secrets lawsuit involving rival base-editing therapies and disputed patent filings. 29 September 2026
Careers
As partner and head of IP for the region, the Hong Kong-based hire brings extensive experience advising on the IP aspects of complex corporate transactions and investments. 29 September 2026
Pharma
Can a drug’s ‘inactive’ precursor qualify for a multi-million pound patent extension? The UK High Court has just delivered a ruling on Takeda's ADHD drug Elvanse, weighing regulatory precedent against a conflicting German decision. 28 September 2026
Careers
The returning shareholder’s work spans the patent lifecycle and includes computerised business methods, polymer compositions, and small molecules. 28 September 2026
Pharma
Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug. 25 September 2026
Pharma
An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court. 24 September 2026